Preclinical developer of therapeutics for obesity, NASH and other liver diseases leveraging a liver‑targeting polymer nanoparticle delivery platform to encapsulate potent drugs. Lead program is an encapsulated thyromimetic that produced significant weight loss in diet‑induced obesity–NASH animal models; pipeline focuses on delivering highly potent drug assets with improved safety and efficacy.